Cor­cept los­es patent fight with Te­va over Cush­ing's syn­drome drug

Cor­cept Ther­a­peu­tics lost its patent in­fringe­ment law­suit against Te­va Phar­ma­ceu­ti­cals over its Cush­ing’s syn­drome drug Ko­r­lym af­ter a New Jer­sey judge ruled in Te­va’s fa­vor.

Cor­cept brought the suit against Te­va, claim­ing that the Is­raeli drug­mak­er’s gener­ic ver­sion of the drug in­fringed on two Cor­cept patents that cov­er meth­ods of safe­ly ad­min­is­ter­ing Ko­r­lym (mifepri­s­tone) with drugs that are strong CYP3A4 in­hibitors. The FDA ap­proved Te­va’s gener­ic in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER